Literature DB >> 28430376

Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.

B Page1, L Borradori1, H Beltraminelli1, N Yawalkar1, R E Hunger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28430376     DOI： 10.1111/jdv.14282

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  8 in total

1.  Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.

Authors:  Emily Coleman; Christine Ko; Feng Dai; Mary M Tomayko; Harriet Kluger; Jonathan S Leventhal
Journal:  J Am Acad Dermatol       Date:  2018-11-03       Impact factor: 11.527

Review 2.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

3.  Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report.

Authors:  Pierre Magdelaine; Adrien Costantini; Lucie Fabre; Etienne Giroux-Leprieur
Journal:  Thorac Cancer       Date:  2022-05-26       Impact factor: 3.223

Review 4.  High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.

Authors:  Alyce M Kuo; Alina Markova
Journal:  Front Med (Lausanne)       Date:  2022-06-13

Review 5.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

6.  "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.

Authors:  Pietro Sollena; Simone Cappilli; Francesco Federico; Giovanni Schinzari; Giampaolo Tortora; Ketty Peris
Journal:  Hum Vaccin Immunother       Date:  2021-03-24       Impact factor: 4.526

7.  Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors:  Isabella Pospischil; Wolfram Hoetzenecker
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

Review 8.  Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Authors:  Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.